Abstract:Objective:To investigate the relationship between short-term blood glucose fluctuation and chronic kidney disease (CKD) in diabetic patients.Methods:In this prospective cohort study, we analyzed the data from the Guiyang subcenter of the Risk Evalution of cAncers in Chinese dibeTic Individual: alONgitudinal (REACTION) Study. A total of 10 140 residents aged over 40 in Yunyan District of Guiyang were selected from the baseline data by cluster sampling from May 2011 to August 2011, and the above subjects were followed up in 2014, and 400 subjects were eventually included in the study. All subjects were surveyed by questionnaire to collect sociodemographic characteristics, height, weight, blood pressure, fasting plasma glucose (FPG), 2 hours postprandial glucose (2hPG), glycated hemoglobin A 1c (HbA 1c), triglyceride (TG), fasting insulin and serum creatinine. The difference between 2hPG and FPG (2hPG-FPG) was used as an index to evaluate short-term blood glucose fluctuations. According to the HbA 1c levels, the subjects were divided into two groups: patients with good glycemic control (HbA 1c<7%) and patients with poor glycemic control (HbA 1c≥7%), The t test, Chi-square test and non-parametric test were used to compare the differences of indicators in each group. Associations between baseline 2hPG-FPG and CKD were performed by Spearman correlation. Associations between baseline 2hPG-FPG and eGFR after 3 years were performed by linear regression. A logistic regression model was used to analyze the relationship between baseline 2hPG-FPG levels (quartiles) and the risk of new CKD at 3 years. Spearman correlation was used to explore the correlation between baseline 2hPG-FPG and CKD, and linear regression analysis was used to analyze the relationship between baseline 2hPG-FPG and estimated glomerular filtration rate (eGFR) at 3 years. Logistic regression model was used to evaluate the relationship between different levels of baseline 2hPG-FPG (quartiles) and the risk of new onset of CKD at 3 years. Results:There were 175 patients in good glycemic control group and 225 patients in poor glycemic control group. In patients with poor glycemic control, the TG, FPG, 2hPG and 2hPG-FPG were higher than those in patients with good glycemic control, and the difference between the two groups was statistically significant ( P<0.05). In patients with poor glycemic control, baseline 2hPG-FPG was negatively correlated with eGFR at 3 years [ β=-1.178, 95% confidence interval (CI) -2.038 to -0.319 , P=0.007], and positively correlated with the likelihood of CKD at 3 years ( r s=0.147, P=0.027). Logistic regression analysis showed that the risk of CKD increased with the increase of baseline 2hPG-FPG level ( P<0.05). After adjusting for gender, age, body mass index, blood pressure, blood lipid, fasting insulin, smoking, alcohol consumption and disease course, in patients with poor glycemic control, the group with the highest baseline 2hPG-FPG level had a significantly increased risk of developing CKD after 3 years (odds ratio 4.474, 95%CI 1.039 to 19.268, P=0.044). Conclusions:In previous diabetes patients with poor glycemic control, higher levels of 2hPG-FPG were associated with an increased risk of CKD after 3 years. 2hPG-FPG may be an independent risk factor for CKD.

The changes and clinical significance of serum YKL-40 level in type 2 diabetic patients with chronic kidney disease

Increased Levels of YKL-40 in Patients with Diabetes Mellitus: a Systematic Review and Meta-Analysis

Association Between Serum YKL-40 Level and Degree of Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus

Correlation of serum YKL-40 with type 2 diabetes

YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria

Serum soluble tumor necrosis factor receptor levels in T2DM patients with early diabetic kidney disease and the clinical implications

Clinical Significance of Determination of Serum Cystatin C,lipoprotein (α) and High Sensitivity C-reactive Protein in Type 2 Diabetic Patients with Early Renal Impairment.

Serum YKL-40 Levels Are Increased in Patients with Diabetes Mellitus and Coronary Artery Diseases: A Meta-analysis

Diagnostic Value of Serum YKL‐40 Level for Coronary Artery Disease: A Meta‐Analysis

Increased YKL-40 Levels Are Linked with Disease Severity of Initially Diagnosed Graves’ Disease

Association between serum YKL-40 levels and endothelial function in hypertensive patients]

YKL-40 (chitinase-3-like protein 1) serum levels are associated with abdominal aortic calcification in hemodialysis patients

Changes and clinical significance of serum level of angiopoietin-2 in T2DM patients

The Change of Serum and Urinary Transforming Growth Factor-Beta-1 and Their Clinical Significances in Type 2 Diabetics

Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes

Short-term blood glucose fluctuations and the risk of chronic kidney disease in diabetic patients: a prospective cohort study

Changes of glomerular filtration rate in type 2 diabetic patients with normal serum creatinine and serum cystatin C

Serum Haptoglobin Levels Are Associated with Renal Function Decline in Type 2 Diabetes Mellitus Patients in a Chinese Han Population.

Association of serum calcium levels with diabetic kidney disease in normocalcemic type 2 diabetes patients: a cross-sectional study

High Serum Bhlhe40 Levels Are Associated with Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Correlation of serum thyrotropin and thyroid hormone levels with diabetic kidney disease: a cross-sectional study